“One person can only do so much, but together we can make a difference.”
Michael James Cuccione, 1985 - 2001

RAISING FUNDS FOR CHILDHOOD CANCER RESEARCH SINCE 1997

STAY IN TOUCH: | | |

CHILDHOOD CANCER RESEARCH PROGRAM

Michael Cuccione Pediatric Oncology Laboratory

The overall premise of the Michael Cuccione Pediatric Oncology Laboratory is that by increasing our understanding of how tumour cells respond to extra- or intracellular signals, we will gain unique insights into the pathways that are specific for tumour cells. Targeting of these pathways can then be used as treatment strategies, while minimizing effects on normal growth.

 

"...Through their [Michael Cuccione Foundation] generous support for program awards and the funding of fellowships and critical equipment, the Michael Cuccione Foundation plays an important role in advancing research. Their support funds the talent we need to make today's discoveries and helps to train the next generation of research stars..."

Dr. Sandra Dunn
Assistant Professor at UBC's Department of Pediatrics
Primary Researcher with the Johal Program in Pediatric Oncology Basic and Translational Research at the
Child & Family Research Centre.

 

It is evident that detailed analysis of cellular signal transduction pathways is central to understanding tumor cell biology. Moreover, the pharmaceutical industry is making an extraordinary effort to exploit molecular targets in signal transduction pathways for the development of new cancer therapeutics.

Childhood Cancer Research Impact Report

The Michael Cuccione Childhood Cancer Research Program continues to grow, and is poised to be a world leader in childhood cancer. With the significant addition of young research scientists, both clinical and in the laboratory, we are certain that BC Children's Hospital and the research institute will continue to offer an increased understanding of childhood cancer and expand the use of treatments, developed here in British Columbia, to children with cancer around the world. Please click here to read our full Impact Report »

One of the difficulties has been to decide which pathways to target. A major research strategy in our group is the characterization of non-random genetic alterations in human cancers as a means to more efficiently identify genes involved in tumorigenesis. We believe that analysis of tumour tissue, as opposed to model systems, is essential for initial identification and characterization of gene products involved in altered signal transduction in human malignancies. Then, once the involved proteins have been identified, model systems to further study their biology, such as transgenic or knock-out mice, can be invoked. For example, cloning of chromosomal translocation breakpoints allowed us to discover several previously unrecognized oncogenes or tumour suppressors in solid tumours. These include the t(21;22) associated EWS-ERG chimeric transcription factor in Ewing tumours (Sorensen et al, Nature Genetics, 1994), the t(12;15) associated ETV6-NTRK3 chimeric tyrosine kinase in pediatric sarcomas (Knezevich et al, Nature Genetics, 1998) and secretory breast carcinoma (Tognon et al, Cancer Cell, 2002), and the novel 6q21 HECT E3 protein-ubiquitin ligase, HACE1, in sporadic Wilms' tumour and neuroblastoma (Anglesio et al, Hum Mol Genet, 2004).

To understand how these proteins might contribute to oncogenesis requires extensive biochemical characterization of not only the proteins themselves but of their protein interactors, enzymatic substrates, or other molecules involved in common signal transduction pathways. Thus, analysis of signaling pathways activated or suppressed by translocation-associated oncoproteins or tumour suppressors forms another other major focus of our research group.

Our strategy has been to focus initially on specific recurrent genetic alterations in childhood cancers. In contrast to most adult malignant tumours, which appear to have complex genetic etiologies, many childhood cancers show recurrent chromosomal rearrangements including translocations. We have found that many of these translocations disrupt key genes regulating signal transduction pathways. For example, some chromosomal translocations lead to oncogenic gene fusions expressing chimeric oncoproteins.

After we identify genes altered by a particular genetic alteration, we quickly shift to biochemical studies to ascertain how the altered genes affect cellular signaling. In this way, we have been able to more efficiently single out those pathways that may be of relevance to particular childhood cancers. An additional strategy in my laboratory is to combine these studies with gene expression profiling using the Affymetrix platform. In fact, the gene expression patterns of a large series of childhood solid tumors are currently being generated through a collaborative study with other Children's Oncology Group institutions. We hope that this combination of cancer biology and cancer genetic studies will allow us to more readily elucidate those pathways that can be uniquely targeted in tumour cells while sparing normal cells.

Once we identify altered gene products and signaling pathways in childhood malignancies, we screen for potential relevance in adult malignancies. For example, we found that the t(12;15) associated ETV6-NTRK3 chimeric tyrosine kinase of pediatric sarcomas is also expressed in secretory breast carcinoma, a variant of (Tognon et al, Cancer Cell, 2002), This has lead to a number of studies focused on NTRK3 signaling in breast cancer. We have also started to screen for alterations HECT E3 protein-ubiquitin ligase, HACE1, in adult malignancies. Interestingly, targeted inactivation of the Hace1 gene in mice, which results in the development of spontaneous, late onset murine tumors. Gamma irradiation or inactivation of a single p53 allele on a Hace1-/- background dramatically increases tumor frequencies. Moreover, loss of Hace1 renders mice highly susceptible to lung cancer in response to alkylating agents. These studies confirm the tumor suppressor activity of Hace1, and suggest a role for this protein in cell stress.

A further strategy we have recently implemented for pathway dissection and analysis is to combine phenotypic screens at the cell level with libraries of reagents that target individual genes or combinations that target several components of a pathway. For cell level phenotypic analysis we have built up a high-content screening core which consists of a GE Incell 1000 analyser coupled to a liquid handling station, a thermo plate handling arm and a plate incubator hotel.

The ability to couple fluorescent tagging of proteins (whether by reporters or antibodies) with sub-cellular localization and morphology has proven to be a powerful phenotypic analysis tool. The high content screening platform (INcell) allows rapid fluorescent or brightfield imaging of multiwell plates (up to 384), followed by automated analysis of fluorescent/morphological phenotypes, for example to measure cell receptor internalisation, nuclear blebbing, cytoskeletal changes, cell division, apoptosis. The liquid handling stations and plate oven hotel allow for reagents to be added or the contents of medium in wells to be changed and for incubations to occur over a long period of time, with plates being moved to the INcell reader periodically for phenotypic assessment. The core is building up a modest library of small molecules and a genome wide library of RNAi and shRNA molecules as probe reagents to conduct genome wide screens for phenotypes at cell level.

The ultimate goal of such studies to use this information to develop novel molecular-based strategies for the treatment of human malignant diseases.

The following research documents are available for your knowledge.

Click to read Business Plan for our Childhood Cancer Research Program & the Michael Cuccione Laboratories at the Research Institute at BC Children's Hospital [PDF format, 170KB]

The following represents an overview of the current state of the Childhood Cancer Research Program (CCRP) of the BCCH and CFRI, in which we will outline the following: a) the current 3 areas of excellence in the group; b) the strategic plans to expand research capacity in each of the 3 areas; and c) how the Michael Cuccione laboratories will integrate within the overall strategic plans for the CCRP. It should be noted that we expect to expand the research efforts of the CCRP to include hematology, but such expansions are beyond the scope of the current strategic plan..

Read Complete Article »

A Census of Human Cancer Genes [PDF format, 174KB]
A central aim of cancer research has been to identify the mutated genes that are causally implicated in oncogenesis ('cancer genes').

After two decades of searching, how many have been identified and how do they compare to the complete gene set that has been revealed by the human genome sequence?

Read Complete Article »

Endless Cycling [PDF format, 441KB]
Stem cells and cancer cells share certain properties, such as plasticity and selfrenewal,
which indicates that they might have common cellular machineries.Tsai and McKay now report in Genes & Development a nucleolar mechanism that regulates cell-cycle progression in stem cells and cancer cells..

Read Complete Article »


Upcoming Fundraising Events

Mark your calendar, come and join us at the following fundraising events! We promise, it will be fun!

The Burrard Public House Fashion Show
Date: November 5, 2014 details

Recently Publicised...

Checkout our news section to learn about the latest developments taking place at our Childhood Cancer Research Program & The Michael Cuccione Pediatric Oncology Laboratory at the Child & Family Research Insitute, BC Children's Hospital.

more latest news

MICHAEL CUCCIONE FOUNDATION GRATEFULLY RECOGNIZES OUR CORPORATE SPONSORS